$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000092706621000166 Filed on October 28, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$2.944B	$2.938B	$2.905B
YoY Change	1.33%	0.49%	0.23%
Cost Of Revenue	$2.060B	$2.009B	$2.057B
YoY Change	0.16%	1.87%	2.81%
Gross Profit	$883.7M	$929.7M	$848.4M
YoY Change	4.17%	-2.37%	-5.52%
Gross Profit Margin	30.02%	31.64%	29.2%
Selling, General & Admin	$322.7M	$293.1M	$304.5M
YoY Change	5.98%	-19.32%	9.38%
% of Gross Profit	36.52%	31.52%	35.89%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$174.8M	$170.5M	$161.5M
YoY Change	8.21%	8.71%	1.89%
% of Gross Profit	19.78%	18.33%	19.04%
Operating Expenses	$497.5M	$463.6M	$466.0M
YoY Change	6.76%	-10.89%	6.66%
Operating Profit	$386.3M	$474.9M	$381.7M
YoY Change	1.2%	8.5%	-17.49%
Interest Expense	-$68.94M	-$64.13M	-$61.30M
YoY Change	12.46%	-5.98%	-32.34%
% of Operating Profit	-17.85%	-13.5%	-16.06%
Other Income/Expense, Net	-$2.388M	-$7.590M	$6.200M
YoY Change	-138.52%	-240.69%	-46.09%
Pretax Income	$314.9M	$394.5M	$327.4M
YoY Change	-3.81%	39.22%	-14.29%
Income Tax	$65.51M	$74.70M	$73.40M
% Of Pretax Income	20.8%	18.94%	22.42%
Net Earnings	$187.5M	$259.8M	$173.8M
YoY Change	7.88%	63.7%	-29.03%
Net Earnings / Revenue	6.37%	8.84%	5.98%
Basic Earnings Per Share		$2.48	$1.56
Diluted Earnings Per Share	$1.789M	$2.36	$1.50
COMMON SHARES
Basic Shares Outstanding	101.9M shares	104.8M shares	112.0M shares
Diluted Shares Outstanding		109.8M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$533.7M	$1.106B	$377.3M
YoY Change	41.48%	45.58%	-67.21%
Cash & Equivalents	$461.9M	$1.046B	$325.0M
Short-Term Investments	$71.82M	$60.29M	$52.29M
Other Short-Term Assets	$165.6M	$161.9M	$253.0M
YoY Change	-34.55%	-1.86%	46.24%
Inventory	$107.4M	$114.1M	$111.6M
Prepaid Expenses
Receivables	$1.958B	$2.028B	$1.824B
Other Receivables	$427.3M	$410.8M	$544.4M
Total Short-Term Assets	$3.168B	$3.840B	$3.149B
YoY Change	0.6%	11.95%	-14.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.480B	$3.463B	$3.522B
YoY Change	-1.19%	1.33%	1.39%
Goodwill	$7.046B	$6.941B	$6.919B
YoY Change	1.84%	1.05%	1.94%
Intangibles	$177.7M	$152.1M	$166.6M
YoY Change	6.67%	28.83%	22.77%
Long-Term Investments	$288.4M	$276.8M	$290.0M
YoY Change	-0.55%	-1.86%
Other Assets	$136.7M	$101.5M	$79.50M
YoY Change	71.92%	5.58%	-31.45%
Total Long-Term Assets	$13.95B	$13.79B	$13.84B
YoY Change	0.82%	1.3%	1.6%
TOTAL ASSETS
Total Short-Term Assets	$3.168B	$3.840B	$3.149B
Total Long-Term Assets	$13.95B	$13.79B	$13.84B
Total Assets	$17.12B	$17.63B	$16.99B
YoY Change	0.78%	3.45%	-1.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$402.0M	$387.7M	$434.3M
YoY Change	-7.42%	-0.2%	7.53%
Accrued Expenses	$1.054B	$1.071B	$1.055B
YoY Change	-0.06%	0.39%	1.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$179.0M	$166.8M	$169.0M
YoY Change	5.93%	1.72%	29.01%
Total Short-Term Liabilities	$2.399B	$2.363B	$2.476B
YoY Change	-3.13%	-5.45%	4.39%
LONG-TERM LIABILITIES
Long-Term Debt	$8.729B	$8.771B	$7.917B
YoY Change	10.26%	11.49%	-0.76%
Other Long-Term Liabilities	$119.2M	$163.1M	$150.1M
YoY Change	-20.59%	10.64%	-6.68%
Total Long-Term Liabilities	$119.2M	$163.1M	$150.1M
YoY Change	-20.59%	10.64%	-6.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.399B	$2.363B	$2.476B
Total Long-Term Liabilities	$119.2M	$163.1M	$150.1M
Total Liabilities	$14.75B	$14.88B	$14.09B
YoY Change	4.67%	6.38%	2.03%
SHAREHOLDERS EQUITY
Retained Earnings	$354.3M	$1.644B	$852.5M
YoY Change	-58.44%	-19.1%	-40.45%
Common Stock	$540.4M	$525.1M	$597.2M
YoY Change	-9.51%	-24.36%	-20.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00	$899.4M	$0.00
YoY Change		-12.55%
Treasury Stock Shares
Shareholders Equity	$755.5M	$1.149B	$1.384B
YoY Change
Total Liabilities & Shareholders Equity	$17.12B	$17.63B	$16.99B
YoY Change	0.78%	3.45%	-1.87%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	$187.5M	$259.8M	$173.8M
YoY Change	7.88%	63.7%	-29.03%
Depreciation, Depletion And Amortization	$174.8M	$170.5M	$161.5M
YoY Change	8.21%	8.71%	1.89%
Cash From Operating Activities	$529.9M	$567.0M	$484.8M
YoY Change	9.3%	17.45%	-28.77%
INVESTING ACTIVITIES
Capital Expenditures	-$188.8M	-$158.2M	-$224.6M
YoY Change	-15.93%	0.01%	2.42%
Acquisitions
YoY Change
Other Investing Activities	-$147.7M	-$6.270M	-$113.4M
YoY Change	30.28%	-108.03%	-240.52%
Cash From Investing Activities	-$336.5M	-$164.5M	-$338.1M
YoY Change	-0.46%	105.09%	143.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-774.4M	-464.2M	-465.1M
YoY Change	66.49%	-82.29%	-32.86%
NET CHANGE
Cash From Operating Activities	529.9M	567.0M	484.8M
Cash From Investing Activities	-336.5M	-164.5M	-338.1M
Cash From Financing Activities	-774.4M	-464.2M	-465.1M
Net Change In Cash	-581.0M	-61.68M	-318.4M
YoY Change	82.48%	-97.22%	111.14%
FREE CASH FLOW
Cash From Operating Activities	$529.9M	$567.0M	$484.8M
Capital Expenditures	-$188.8M	-$158.2M	-$224.6M
Free Cash Flow	$718.7M	$725.2M	$709.4M
YoY Change	1.31%	13.15%	-21.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000927066
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109933000	shares
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	dva	Corporate Integrity Agreement Period CorporateIntegrityAgreementPeriod	P5Y
CY2020Q4	dva	Terminated Remaining Prior Share Repurchases Authorized Amount TerminatedRemainingPriorShareRepurchasesAuthorizedAmount	329302000	USD
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	1-14106
	dei	Entity Registrant Name EntityRegistrantName	DAVITA INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	51-0354549
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2000 16th Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Denver,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80202
	dei	City Area Code CityAreaCode	720
	dei	Local Phone Number LocalPhoneNumber	631-2100
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	101900000	shares
CY2021Q3	dva	Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts	2837940000	USD
	dei	Trading Symbol TradingSymbol	DVA
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q3	dva	Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts	2781650000	USD
	dva	Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts	8370484000	USD
	dva	Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts	8253128000	USD
CY2021Q3	us-gaap	Other Income OtherIncome	100379000	USD
CY2020Q3	us-gaap	Other Income OtherIncome	142416000	USD
	us-gaap	Other Income OtherIncome	304346000	USD
	us-gaap	Other Income OtherIncome	392154000	USD
CY2021Q3	us-gaap	Revenues Revenues	2938319000	USD
CY2020Q3	us-gaap	Revenues Revenues	2924066000	USD
	us-gaap	Revenues Revenues	8674830000	USD
	us-gaap	Revenues Revenues	8645282000	USD
CY2021Q3	dva	Patient Care Costs PatientCareCosts	2008589000	USD
CY2020Q3	dva	Patient Care Costs PatientCareCosts	1971719000	USD
	dva	Patient Care Costs PatientCareCosts	5912196000	USD
	dva	Patient Care Costs PatientCareCosts	5931732000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	293095000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	363280000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	872612000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	943065000	USD
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	170462000	USD
CY2020Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	156894000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	505852000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	468949000	USD
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8704000	USD
CY2020Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5496000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	23785000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	27681000	USD
CY2021Q3	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	0	USD
CY2020Q3	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	0	USD
	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	0	USD
	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	-16252000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	2463442000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	2486397000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	7266875000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	7332317000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	474877000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	437669000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1407955000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1312965000	USD
CY2021Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	72829000	USD
CY2020Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	73658000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	213167000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	243642000	USD
CY2021Q3	dva	Debt Prepayment Refinancing Redemption Charges DebtPrepaymentRefinancingRedemptionCharges	0	USD
CY2020Q3	dva	Debt Prepayment Refinancing Redemption Charges DebtPrepaymentRefinancingRedemptionCharges	86074000	USD
	dva	Debt Prepayment Refinancing Redemption Charges DebtPrepaymentRefinancingRedemptionCharges	0	USD
	dva	Debt Prepayment Refinancing Redemption Charges DebtPrepaymentRefinancingRedemptionCharges	89022000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7590000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5395000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8766000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10590000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	394458000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	283332000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1203554000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	990891000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	74704000	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	58866000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65792000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	241224000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	240564000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	319754000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	217540000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	962330000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	750327000	USD
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	9980000	USD
CY2021Q3	us-gaap	Profit Loss ProfitLoss	319754000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	217540000	USD
	us-gaap	Profit Loss ProfitLoss	962330000	USD
	us-gaap	Profit Loss ProfitLoss	760307000	USD
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	60000000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	171353000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	160438000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	259754000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	158674000	USD
	us-gaap	Net Income Loss NetIncomeLoss	790977000	USD
	us-gaap	Net Income Loss NetIncomeLoss	599869000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.48
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.31
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	7.41
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.81
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.48
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.41
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.89
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.36
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.28
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	7.08
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	4.72
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.36
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.80
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104793000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	120905000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106685000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	122582000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109838000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123954000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111666000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	124927000	shares
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	259754000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	158674000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	790977000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	589889000	USD
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	9980000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	259754000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	158674000	USD
	us-gaap	Net Income Loss NetIncomeLoss	790977000	USD
	us-gaap	Net Income Loss NetIncomeLoss	599869000	USD
CY2021Q3	us-gaap	Profit Loss ProfitLoss	319754000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	217540000	USD
	us-gaap	Profit Loss ProfitLoss	962330000	USD
	us-gaap	Profit Loss ProfitLoss	760307000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-357000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-1628000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	2466000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-16470000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-1034000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-1034000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-3100000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	544376000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	69060000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-4280000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-54528000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	13171000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-59162000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-62842000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-53851000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	12577000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-53596000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-75032000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	265903000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	230117000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	908734000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	685275000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	60000000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	58866000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	171353000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	76387000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	160438000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	205903000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	171251000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	737381000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	524837000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1045742000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	324958000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	92867000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	176832000	USD
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	26690000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	20101000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2027599000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1824282000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	114096000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	111625000	USD
CY2021Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	410796000	USD
CY2021Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	52688000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	70163000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	3839538000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	3148724000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	4838262000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	4480429000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3463212000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3521824000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2860172000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2863089000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	66455000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	70141000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	152121000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	166585000	USD
CY2021Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	243163000	USD
CY2020Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	257491000	USD
CY2021Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	33598000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	32193000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	101469000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79501000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	6940667000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	6919109000	USD
CY2021Q3	us-gaap	Assets Assets	17633940000	USD
CY2020Q4	us-gaap	Assets Assets	16988516000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	387712000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	434253000	USD
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	723080000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	810529000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	683045000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	685555000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	388089000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	369497000	USD
CY2021Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	166818000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	168541000	USD
CY2021Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	14309000	USD
CY2021Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8770883000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	7917263000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	163051000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	150060000	USD
CY2021Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	868078000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	7768000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2363053000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2476143000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2716707000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2738670000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	809600000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	14881772000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	14091736000	USD
CY2021Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1423917000	USD
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1330028000	USD
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110886000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	103136000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	109933000	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	111000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	110000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	525009000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	597073000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1643514000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	852537000	USD
CY2021Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7750000	shares
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2021Q3	us-gaap	Treasury Stock Value TreasuryStockValue	899447000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-119750000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-66154000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1149437000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1383566000	USD
CY2021Q3	us-gaap	Minority Interest MinorityInterest	178814000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	183186000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1328251000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1566752000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17633940000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16988516000	USD
	us-gaap	Profit Loss ProfitLoss	962330000	USD
	us-gaap	Profit Loss ProfitLoss	760307000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	505852000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	468949000	USD
	dva	Debt Refinancing Charges DebtRefinancingCharges	0	USD
	dva	Debt Refinancing Charges DebtRefinancingCharges	86957000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	75898000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	67217000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	56724000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	191783000	USD
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	1687000	USD
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-3026000	USD
	dva	Gain Loss On Disposition Of Business Interests Before Tax GainLossOnDispositionOfBusinessInterestsBeforeTax	0	USD
	dva	Gain Loss On Disposition Of Business Interests Before Tax GainLossOnDispositionOfBusinessInterestsBeforeTax	-16252000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-13418000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	7980000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	205792000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12405000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2490000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8445000	USD
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-144967000	USD
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	62025000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	19663000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1853000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-47412000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	445000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-7176000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-12124000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-87842000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	123833000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	22609000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-100160000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-8748000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-19547000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1400988000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1494230000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	451909000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	449896000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	45143000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	112597000	USD
	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	46578000	USD
	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	83339000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	13274000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	147829000	USD
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	2609000	USD
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	3388000	USD
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	13274000	USD
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	148341000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	11976000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	3434000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	745000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	7925000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	9613000	USD
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	1592000	USD
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	902000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-448185000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-487307000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1613036000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3826484000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	812659000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	3927411000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	9091000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	105705000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	882411000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1025878000	USD
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	177146000	USD
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	179098000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	59849000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	3838000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-308603000	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	6782000	USD
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	28295000	USD
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	32854000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	2880000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	11658000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1381698000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-7381000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-16606000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	636819000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-391381000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	501790000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1208718000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1138609000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	817337000	USD
CY2021Q3	us-gaap	Revenues Revenues	2938319000	USD
CY2020Q3	us-gaap	Revenues Revenues	2924066000	USD
	us-gaap	Revenues Revenues	8674830000	USD
	us-gaap	Revenues Revenues	8645282000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	158674000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	790977000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	589889000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	259754000	USD
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	9980000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	259754000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	158674000	USD
	us-gaap	Net Income Loss NetIncomeLoss	790977000	USD
	us-gaap	Net Income Loss NetIncomeLoss	599869000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	104793000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	120905000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	106685000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	122582000	shares
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	5045000	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3049000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	4981000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2345000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109838000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123954000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111666000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	124927000	shares
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.48
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.31
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	7.41
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.81
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.08
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.48
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.41
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.89
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.36
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.28
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	7.08
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	4.72
CY2021Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0
CY2020Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0.08
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.36
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.80
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	141000	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2765000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	103000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3063000	shares
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	92867000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	176832000	USD
CY2021Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	8225000	USD
CY2021Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	52063000	USD
CY2021Q3	us-gaap	Marketable Securities MarketableSecurities	60288000	USD
CY2020Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	8217000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	44077000	USD
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	52294000	USD
CY2021Q3	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	8225000	USD
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	26690000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	8217000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	20101000	USD
CY2021Q3	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	USD
CY2021Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	33598000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	32193000	USD
CY2021Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	8225000	USD
CY2021Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	52063000	USD
CY2021Q3	us-gaap	Marketable Securities MarketableSecurities	60288000	USD
CY2020Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	8217000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	44077000	USD
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	52294000	USD
CY2021Q3	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	10314000	USD
	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	1986000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	6787635000	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	130057000	USD
CY2020	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	8293000	USD
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-9710000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	6919109000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	53619000	USD
	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	623000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	31438000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	6940667000	USD
CY2021Q3	us-gaap	Goodwill Gross GoodwillGross	7069661000	USD
CY2021Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	128994000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	6940667000	USD
CY2021Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.189
CY2020Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.232
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.200
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.243
CY2021Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8997470000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8163521000	USD
CY2021Q3	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	59769000	USD
CY2020Q4	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	77717000	USD
CY2021Q3	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	8937701000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	8085804000	USD
CY2021Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	166818000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	168541000	USD
CY2021Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8770883000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	7917263000	USD
CY2021Q3	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0334
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0326
CY2021Q3	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0334
CY2021Q3	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.51
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">contingencies</span><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations (which frequently arise from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of September 30, 2021 and December 31, 2020, the Company’s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">2016 U.S. Attorney Texas Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: In February 2016, DaVita Rx, LLC (DaVita Rx), a wholly-owned subsidiary of the Company, received a Civil Investigative Demand (CID) from the U.S. Attorney’s Office, Northern District of Texas. The government is conducting a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as an investigation into the Company’s relationships with pharmaceutical manufacturers. The government’s investigation covers the period from January 1, 2006 through December 31, 2018. In December 2017, the Company finalized and executed a settlement agreement that resolved certain of the issues in the government’s investigation and that included total monetary consideration of $63,700, as previously disclosed, of which $41,500 was an incremental cash payment and $22,200 was for amounts previously refunded, and all of which was previously accrued. The government’s investigation is ongoing with respect to issues related to DaVita Rx’s historic relationships with certain pharmaceutical manufacturers, and in July 2018 the Office of Inspector General (OIG) served the Company with a subpoena seeking additional documents and information relating to those relationships. On September 15, 2021, the U.S. Attorney’s Office notified the U.S. District Court, Northern District of Texas, of its decision and the decision of 31 states not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. ex rel. Doe v. DaVita Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The court then unsealed the complaint, which alleges violations of the FCA, by order dated September 17, 2021. The complaint has not been served on the Company to date. The Company disputes the allegations in the complaint. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney’s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company’s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is continuing to cooperate with the government in this investigation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2018 U.S. Attorney Florida Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2018, DaVita Labs received two CIDs from the U.S. Attorney’s Office, Middle District of Florida that were identical in nature but directed to the two different labs. According to the face of the CIDs, the U.S. Attorney’s Office is conducting an investigation as to whether the Company’s subsidiary submitted claims for blood, urine, and fecal testing, where there were insufficient test validation or stability studies to ensure accurate results, in violation of the FCA. In October 2018, DaVita Labs received a subpoena from the OIG in connection with this matter requesting certain patient records linked to clinical laboratory tests. On September 30, 2019, the U.S. Attorney’s Office notified the U.S. District Court, Middle District of Florida, of its decision not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Lorne Holland, et al. v. DaVita Healthcare Partners, Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The court then unsealed the complaint, which alleges violations of the FCA, by order dated the same day. In January 2020, the private party relators served the Company and DaVita Labs with an amended complaint. The Company and DaVita Labs answered the complaint on July 23, 2020. On August 10, 2021, the court entered summary judgment in favor of the Company and DaVita Labs on all of the relators’ FCA claims leaving only the claims for retaliation. The court dismissed the case on October 13, 2021. On October 15, 2021, the parties signed an agreement to resolve the remaining retaliation claims for an immaterial amount. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney’s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney’s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company’s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company’s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients’ decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is cooperating with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Department of Justice Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In October 2020, the Company received a CID from the Department of Justice pursuant to a False Claims Act investigation concerning allegations that DaVita Medical Group (DMG) may have submitted undocumented or unsupported diagnosis codes in connection with Medicare Advantage beneficiaries. The CID covers the period from January 1, 2015 through June 19, 2019, the date the Company completed the divestiture of DMG to Collaborative Care Holdings, LLC. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Proceedings</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The two count indictment alleges that purported agreements entered into by its former chief executive officer not to solicit senior-level employees violate Section 1 of the Sherman Act. On September 14, 2021, DaVita and its former chief executive officer filed a motion to dismiss the indictment. On July 16, 2021, a former DaVita employee filed a putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Pena v. Surgical Care Affiliates, LLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in the U.S. District Court, Northern District of Illinois based on the allegations in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. v. DaVita Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. On August 6, 2021, the plaintiff in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Pena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed a notice of voluntary dismissal and the court dismissed the complaint on August 9, 2021. On August 9, 2021, DaVita was named as defendant in a consolidated class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Outpatient Medical Center Employee Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in the U.S. District Court, Northern District of Illinois. This class action complaint seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On October 18, 2021, the Company filed a motion to dismiss the class action complaint.The Company disputes the allegations in the indictment and the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend these actions accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> * </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 9, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company’s business, results of operations, financial condition, cash flows or reputation.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Resolved Matters</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Peace Officers’ Annuity and Benefit Fund of Georgia Securities Class Action Civil Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On February 1, 2017, the Peace Officers’ Annuity and Benefit Fund of Georgia filed a putative federal securities class action complaint in the U.S. District Court for the District of Colorado against the Company and certain executives. The complaint covers the time period of August 2015 to October 2016 and alleges, generally, that the Company and its executives violated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal securities laws concerning the Company’s financial results and revenue derived from patients who received charitable premium assistance from an industry-funded non-profit organization. The complaint further alleges that the process by which patients obtained commercial insurance and received charitable premium assistance was improper and "created a false impression of DaVita’s business and operational status and future growth prospects."</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While the Company continues to dispute the allegations, it reached an agreement to resolve this matter without admitting to any liability. Settlement of this matter was covered primarily with insurance proceeds. The Company contributed an amount that did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows. On April 13, 2021, the court granted final approval of the settlement. On August 9, 2021, the court entered final judgment and dismissed all claims in the action with prejudice.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">In re DaVita Inc. Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On August 15, 2017, the U.S. District Court for the District of Delaware consolidated three previously disclosed shareholder derivative lawsuits: the Blackburn Shareholder action filed on February 10, 2017, the Gabilondo Shareholder action filed on May 30, 2017, and the City of Warren Police and Fire Retirement System Shareholder action filed on June 9, 2017. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the defendants continue to dispute the allegations, an agreement was reached to resolve this matter without admitting to any liability and the court approved the settlement and entered final judgment and dismissed the case with prejudice on January 29, 2021. As part of the settlement, the Company agreed to certain corporate governance policies, but did not make any financial contribution towards the settlement.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> * *</span></div>
	dva	Corporate Integrity Agreement Expiration Date CorporateIntegrityAgreementExpirationDate	2019-10-22
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	179110000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
CY2021Q3	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	2731000	shares
CY2020Q3	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	8232000	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	7750000	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	12284000	shares
CY2021Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	336217000	USD
CY2020Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	725439000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	899447000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1028578000	USD
CY2021Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	123.14
CY2020Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	88.13
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	116.06
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	83.73
CY2020Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	2000000000	USD
CY2021Q3	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	49501000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	9980000	USD
CY2021Q3	dva	Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average Ebitda Multiple PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple	180000000	USD
CY2021Q3	us-gaap	Revenues Revenues	2938319000	USD
CY2020Q3	us-gaap	Revenues Revenues	2924066000	USD
	us-gaap	Revenues Revenues	8674830000	USD
	us-gaap	Revenues Revenues	8645282000	USD
CY2021Q3	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	28153000	USD
CY2020Q3	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	25841000	USD
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	79093000	USD
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	122514000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	474877000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	437669000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1407955000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1312965000	USD
CY2021Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	72829000	USD
CY2020Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	73658000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	213167000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	243642000	USD
CY2021Q3	dva	Debt Prepayment Refinancing Redemption Charges DebtPrepaymentRefinancingRedemptionCharges	0	USD
CY2020Q3	dva	Debt Prepayment Refinancing Redemption Charges DebtPrepaymentRefinancingRedemptionCharges	86074000	USD
	dva	Debt Prepayment Refinancing Redemption Charges DebtPrepaymentRefinancingRedemptionCharges	0	USD
	dva	Debt Prepayment Refinancing Redemption Charges DebtPrepaymentRefinancingRedemptionCharges	89022000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7590000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5395000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8766000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10590000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	394458000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	283332000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1203554000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	990891000	USD
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	170462000	USD
CY2020Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	156894000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	505852000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	468949000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	451909000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	449896000	USD
CY2021Q3	us-gaap	Assets Assets	17633940000	USD
CY2020Q4	us-gaap	Assets Assets	16988516000	USD

Files In Submission

Name	View Source	Status
0000927066-21-000166-index-headers.html	Edgar Link	pending
0000927066-21-000166-index.html	Edgar Link	pending
0000927066-21-000166.txt	Edgar Link	pending
0000927066-21-000166-xbrl.zip	Edgar Link	pending
dva-20210930.htm	Edgar Link	pending
dva-20210930.xsd	Edgar Link	pending
dva-20210930_cal.xml	Edgar Link	unprocessable
dva-20210930_def.xml	Edgar Link	unprocessable
dva-20210930_g1.jpg	Edgar Link	pending
dva-20210930_htm.xml	Edgar Link	completed
dva-20210930_lab.xml	Edgar Link	unprocessable
dva-20210930_pre.xml	Edgar Link	unprocessable
dva-93021ex101x2021davitai.htm	Edgar Link	pending
dva-93021ex31110xq.htm	Edgar Link	pending
dva-93021ex31210xq.htm	Edgar Link	pending
dva-93021ex32110xq.htm	Edgar Link	pending
dva-93021ex32210xq.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2021 Q4 Form 10-Q Financial Statement

#000092706621000166 Filed on October 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2021 Q4 Form 10-Q Financial Statement

#000092706621000166 Filed on October 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva